References
- Al-Shaikhly T, Ochs HD. Hyper IgE syndromes: clinical and molecular characteristics. Immunol Cell Biol. 2019;97(4):368–379. doi:10.1111/imcb.12209.
- Szczawinska-Poplonyk A, Kycler Z, Pietrucha B, Heropolitanska-Pliszka E, Breborowicz A, Gerreth K. The hyperimmunoglobulin E syndrome clinical manifestation diversity in primary immune deficiency. Orphanet J Rare Dis. 2011;6:76. doi:10.1186/1750-1172-6-76.
- Chu EY, Freeman AF, Jing H, et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol. 2012;148(1):79–84. doi:10.1001/archdermatol.2011.262.
- Engelhardt KR, Gertz ME, Keles S, Schäffer AA, Sigmund EC, Glocker C. The extended clinical phenotype of 64 patients with DOCK8 deficiency. J Allergy Clin Immunol. 2015;136(2):402–412. doi:10.1016/j.clim.2016.08.002.
- Biggs C, Keles S, Chatila T. DOCK8 deficiency: insights into pathophysiology, clinical features and management. Clin Immunol. 2017;181:75–82. doi:10.1016/j.clim.2017.06.003.
- Orhan M, Ozkan Y, Irkec M. Eye involvement in hyperimmunoglobulinemia E (Job’s) syndrome. J Pediatr Ophthalmol Strabismus. 2001;38:313–314.
- Arora V, Kim UR, Khazei HM, Kusagur S. Ophthalmic complications including retinal detachment in hyperimmunoglobulinemia E (Job’s) syndrome: case report and review of literature. Indian J Ophthalmol. 2009;57(5):385–386. doi:10.4103/0301-4738.55076.
- Haslett RS, Moriarty AP, Vijayadurai P, McGalliard JN, Chandna A. Candida endophthalmitis in Job syndrome. Arch Ophthalmol. 1996;114(5):617–618. doi:10.1001/archopht.1996.01100130609023.
- Destafeno JJ, Kodsi SR, Primack JD. Recurrent Staphylococcus aureus chalazia in hyperimmunoglobulinemia E (Job’s) syndrome. Am J Ophthalmol. 2004;138(6):1057–1058. doi:10.1016/j.ajo.2004.06.034.
- Patteri P, Serru A, Chessa ML, Loi M, Pinna A. Recurrent giant chalazia in hyperimmunoglobulin E (Job’s) syndrome. Int Ophthalmol. 2009;29(5):415–417. doi:10.1007/s10792-008-9238-y.
- Crama N, Toolens AM, van der Meer JW, Cruysberg JR. Giant chalazia in the hyperimmunoglobulinemia E (hyper-IgE) syndrome. Eur J Ophthalmol. 2004;14(3):258–260. doi:10.1177/112067210401400311.
- McGhee SA, Chatila TA. DOCK8 immune deficiency as a model for primary cytoskeletal dysfunction. Dis Markers. 2010;29(3–4):151–156. doi:10.3233/DMA-2010-0740.
- Ham H, Guerrier S, Kim J, et al. Dedicator of cytokinesis 8 interacts with talin and Wiskott-Aldrich syndrome protein to regulate NK cell cytotoxicity. J Immunol. 2013;190(7):3661–3669. doi:10.4049/jimmunol.1202792.
- Zhang Q, Davis JC, Dove CG, Su HC. Genetic, clinical, and laboratory markers for DOCK8 immunodeficiency syndrome. Dis Markers. 2010;29(3–4):131–139. doi:10.3233/DMA-2010-0737.
- Lambe T, Crawford G, Johnson AL, et al. DOCK8 is essential for T-cell survival and the maintenance of CD8+ T-cell memory. Eur J Immunol. 2011;41(12):3423–3435. doi:10.1002/eji.201141759.
- Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361(21):2046–2055. doi:10.1056/NEJMoa0905506.
- Nieves-Moreno M, Granados M, Noval S. Primary immunodeficiency diseases presenting with chalazia as the first manifestation. Ocul Immunol Inflamm. 2020 Aug;24:1–3. doi:10.1080/09273948.2020.1794012.